Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression.
Frontiers in Psychiatry 2025 Jian-Qiang Tan, Li-Mei Gu, Yan-Ling Zhou et al. 2 citations
We aimed to explore the correlation between baseline body mass index (BMI) and the antidepressant properties of intravenous ketamine in patients with depression. We divided 135 patients diagnosed with either major depressive disorder (n=103) or bipolar depression (n=32) into lower and higher BMI groups based on their baseline BMI. Patients with a lower BMI (BMI0.05). The linear mixed models...